Lifescience Global




Brain Tumor Stem Cells and Immunotherapy - Pages 28-38

Isako Saga and Masahiro Toda

Department of Neurosurgery, Keio University School of Medicine, Tokyo, Japan





  • Additional Information

    Abstract: Glioblastoma multiforme (GBM) is one of the most common aggressive primary brain tumors, and it responds poorly to the current treatment combination of surgery, radio-, and chemotherapy. The hypothesis that cancer stem cells may account for the pathogenesis underlying various tumors, including GBM, has been accepted widely in recent years. Brain tumor stem cells (BTSCs) have been shown to contribute to therapeutic resistance and the presence of BTSCs may explain the recurrence of GBM following conventional treatment, as just a few BTSCs are sufficient to give rise to a new tumor. Therefore, the therapeutic targeting of BTSCs is of utmost importance. Among emerging treatment modalities, immunotherapy is a strategy that has the potential to target BTSCs that are resistant to conventional therapies. This review describes recent advancements in the study of BTSCs and immunotherapy.

    Keywords: Glioma, glioblastoma, cancer stem cell, niche, immunoresistance, peptide vaccine, EGFRvIII, WT1, dendritic cell, SOX6.


    ♦  Worldwide readership
    ♦  High quality content
    ♦  Maximum visibility
    ♦  Efficient publishing
    ♦  Optional Open Access

    Publish your Research


    As an author what type of publishing model you prefer?

    Open Access
    Optional Open Access
    Subscription based
    5 Votes left